...
首页> 外文期刊>Journal of Clinical Microbiology >Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection
【24h】

Highly Multiplexed Proteomic Analysis of Quantiferon Supernatants To Identify Biomarkers of Latent Tuberculosis Infection

机译:Quantiferon上清液的高度复用蛋白质组学分析,以鉴定潜伏性结核感染的生物标志物

获取原文
           

摘要

The tests for diagnosing latent tuberculosis infection (LTBI) are limited by a poor predictive value for identifying people at the highest risk for progressing to active tuberculosis (TB) and have various sensitivities and specificities in different populations. Identifying a more robust signature for LTBI is important for TB prevention and elimination. A pilot study was conducted with samples from immigrants to the United States that were screened for LTBI by the three commercially approved tests, namely, the tuberculin skin test (TST), the Quantiferon-TB Gold in-tube (QFT-GIT), and the T-SPOT.TB (T-SPOT). QFT-GIT supernatants from 13 people with concordant positive results and 26 people with concordant negative results were analyzed via the highly multiplexed SOMAscan proteomic assay. The proteins in the stimulated supernatants that distinguished LTBI from controls included interleukin-2 (IL-2), monocyte chemotactic protein 2 (MCP-2), interferon gamma inducible protein-10 (IP-10), interferon gamma (IFN-γ), tumor necrosis factor superfamily member 14 (TNFSF14, also known as LIGHT), monokine induced by gamma interferon (MIG), and granzyme B (P <0.00001). In addition, antigen stimulation increased the expression of heparin-binding EGF-like growth factor (HB-EGF) and activin AB in LTBI samples. In nil tubes, LIGHT was the most significant marker (P <0.0001) and was elevated in LTBI subjects. Other prominent markers in nonstimulated QFT-GIT supernatants were the complement-3 components C3b, iC3b, and C3d, which were upregulated in LTBI and markedly decreased upon stimulation. We found known and novel proteins that warrant further studies for developing improved tests for LTBI, for predicting progression to active disease, and for discriminating LTBI from active TB.
机译:诊断潜伏性结核感染(LTBI)的测试受限于无法识别出患上活动性肺结核(TB)风险最高的人的预测价值,并且在不同人群中具有各种敏感性和特异性。为LTBI的预防和消除,识别出更健壮的LTBI签名非常重要。对来自美国移民的样本进行了一项初步研究,该样本通过三种商业认可的测试进行了LTBI筛查,即结核菌素皮肤测试(TST),Quantiferon-TB金管内测试(QFT-GIT)和T-SPOT.TB(T-SPOT)。通过高度多重的SOMAscan蛋白质组分析,分析了来自13名具有一致阳性结果和26名具有阴性阴性结果的QFT-GIT上清液。刺激的上清液中将LTBI与对照区分开的蛋白质包括白介素2(IL-2),单核细胞趋化蛋白2(MCP-2),γ干扰素诱导型蛋白10(IP-10),γ干扰素(IFN-γ)。 ,肿瘤坏死因子超家族成员14(TNFSF14,也称为LIGHT),γ干扰素(MIG)诱导的单因子和粒酶B( P <0.00001)。此外,抗原刺激增加了LTBI样品中肝素结合性EGF样生长因子(HB-EGF)和激活素AB的表达。在无试管中,LIGHT是最显着的标志物( P <0.0001),在LTBI受试者中升高。未刺激的QFT-GIT上清液中的其他显着标志物是补体3组分C3b,iC3b和C3d,它们在LTBI中上调并在刺激后显着降低。我们发现了已知且新颖的蛋白质,值得进一步研究以开发针对LTBI的改进测试,预测向活动性疾病的进展以及将LTBI与活动性结核区分开。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号